Cortex Pharmaceuticals, Inc.
Single Pharmaceutical-based Strategy Aims To Solve Neurological And Psychiatric Disorders
An emerging microcap firm out of Irvine, California is developing novel drug therapies for the treatment of neurological and psychiatric disorders.
Servier Exercises Option to Cortex’s AMPAKINE® CX1632, An Innovative Compound in Clinical Development for Alzheimer's Disease
Cortex to Receive an additional $2 Million
Cortex Announces Revised Date for CEO Presentation at Rodman & Renshaw’s 13th Annual Healthcare Conference on September 12, 2011
Cortex Pharmaceuticals, Inc. (OTCBB:CORX.ob) President and CEO, Mark A.
Cortex’s CEO to Present at Rodman & Renshaw’s 13th Annual Healthcare Conference on September 13, 2011
Cortex Pharmaceuticals, Inc. (OTCBB:CORX.ob) President and CEO, Mark A.
Cortex Receives U.S. Patent for the Use of AMPAKINE Molecules to Treat Respiratory Depression
Cortex Pharmaceuticals, Inc. (OTCBB:CORX.ob) announced that it has received a Notice of Allowance from the U.S.
Cortex Enters into New Agreement with Servier
Cortex To Recieve Up To $3 Million If Servier Option Is Exercised.
